139 related articles for article (PubMed ID: 24690205)
1. Effects of testosterone treatment on bone mineral density in hypogonadal men receiving intrathecal opioids.
Finch PM; Price LM; Pullan PT; Drummond PD
Pain Pract; 2015 Apr; 15(4):308-13. PubMed ID: 24690205
[TBL] [Abstract][Full Text] [Related]
2. Hypogonadism in men with chronic pain linked to the use of long-acting rather than short-acting opioids.
Rubinstein AL; Carpenter DM; Minkoff JR
Clin J Pain; 2013 Oct; 29(10):840-5. PubMed ID: 24384986
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and influence of diagnostic criteria in the assessment of hypogonadism in intrathecal opioid therapy patients.
Duarte RV; Raphael JH; Labib M; Southall JL; Ashford RL
Pain Physician; 2013 Jan; 16(1):9-14. PubMed ID: 23340538
[TBL] [Abstract][Full Text] [Related]
4. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.
Behre HM; Kliesch S; Leifke E; Link TM; Nieschlag E
J Clin Endocrinol Metab; 1997 Aug; 82(8):2386-90. PubMed ID: 9253305
[TBL] [Abstract][Full Text] [Related]
5. Endocrine consequences of long-term intrathecal administration of opioids.
Abs R; Verhelst J; Maeyaert J; Van Buyten JP; Opsomer F; Adriaensen H; Verlooy J; Van Havenbergh T; Smet M; Van Acker K
J Clin Endocrinol Metab; 2000 Jun; 85(6):2215-22. PubMed ID: 10852454
[TBL] [Abstract][Full Text] [Related]
6. Opioid-induced hypogonadism: why and how to treat it.
De Maddalena C; Bellini M; Berra M; Meriggiola MC; Aloisi AM
Pain Physician; 2012 Jul; 15(3 Suppl):ES111-8. PubMed ID: 22786450
[TBL] [Abstract][Full Text] [Related]
7. Effects of long-term testosterone substitutive therapy on bone mineral content in men with hypergonadotrophic hypogonadism.
Medras M; Jankowska EA; Rogucka E
Andrologia; 2001 Jan; 33(1):47-52. PubMed ID: 11167519
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement.
Ishizaka K; Suzuki M; Kageyama Y; Kihara K; Yoshida K
Asian J Androl; 2002 Jun; 4(2):117-21. PubMed ID: 12085102
[TBL] [Abstract][Full Text] [Related]
9. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain.
Daniell HW
J Pain; 2008 Jan; 9(1):28-36. PubMed ID: 17936076
[TBL] [Abstract][Full Text] [Related]
10. Hypogonadism in patients treated with intrathecal morphine.
Finch PM; Roberts LJ; Price L; Hadlow NC; Pullan PT
Clin J Pain; 2000 Sep; 16(3):251-4. PubMed ID: 11014399
[TBL] [Abstract][Full Text] [Related]
11. Androgen deficiency in long-term intrathecal opioid administration.
Kim CH; Garcia R; Stover J; Ritchie K; Whealton T; Ata MA
Pain Physician; 2014; 17(4):E543-8. PubMed ID: 25054405
[TBL] [Abstract][Full Text] [Related]
12. The Role of Testosterone Supplemental Therapy in Opioid-Induced Hypogonadism: A Retrospective Pilot Analysis.
Raheem OA; Patel SH; Sisul D; Furnish TJ; Hsieh TC
Am J Mens Health; 2017 Jul; 11(4):1208-1213. PubMed ID: 28625114
[TBL] [Abstract][Full Text] [Related]
13. [Effect of immunosuppression-induced hypogonadism on bone metabolism after heart transplantation].
Stief J; Sohn HY; Alt A; Uberfuhr P; Theisen K; Stempfle HU
Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1674-8. PubMed ID: 15273918
[TBL] [Abstract][Full Text] [Related]
14. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men.
Leifke E; Körner HC; Link TM; Behre HM; Peters PE; Nieschlag E
Eur J Endocrinol; 1998 Jan; 138(1):51-8. PubMed ID: 9461316
[TBL] [Abstract][Full Text] [Related]
15. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.
Katznelson L; Finkelstein JS; Schoenfeld DA; Rosenthal DI; Anderson EJ; Klibanski A
J Clin Endocrinol Metab; 1996 Dec; 81(12):4358-65. PubMed ID: 8954042
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism.
Zacharin MR; Pua J; Kanumakala S
Clin Endocrinol (Oxf); 2003 Jun; 58(6):691-5. PubMed ID: 12780744
[TBL] [Abstract][Full Text] [Related]
17. Does opioid use for pain management warrant routine bone mass density screening in men?
Fortin JD; Bailey GM; Vilensky JA
Pain Physician; 2008; 11(4):539-41. PubMed ID: 18690281
[TBL] [Abstract][Full Text] [Related]
18. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study.
Aversa A; Bruzziches R; Francomano D; Greco EA; Fornari R; Di Luigi L; Lenzi A; Migliaccio S
Aging Male; 2012 Jun; 15(2):96-102. PubMed ID: 22439807
[TBL] [Abstract][Full Text] [Related]
19. Opioid-Induced Androgen Deficiency (OPIAD): Diagnosis, Management, and Literature Review.
O'Rourke TK; Wosnitzer MS
Curr Urol Rep; 2016 Oct; 17(10):76. PubMed ID: 27586511
[TBL] [Abstract][Full Text] [Related]
20. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover.
Guo CY; Jones TH; Eastell R
J Clin Endocrinol Metab; 1997 Feb; 82(2):658-65. PubMed ID: 9024272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
